Publications by authors named "Donald VanDevanter"

Claim this Profile
C
Correlates of FEV₁ deficit in pulmonary exacerbations of cystic fibrosis and associated clinical outcomes.
Oliver J McElvaney, Sonya L Heltshe, Don B Sanders, Natalie E West, Barbra Fogarty, Donald R VanDevanter

J Cyst Fibros· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Evaluating the association of antibiotic spectrum and treatment responses of cystic fibrosis pulmonary exacerbations.
Ranjani Somayaji, Jonathan D Cogen, Donald VanDevanter, John J LiPuma, Natalie E West

J Cyst Fibros· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Cannabinoid receptor 2 agonist, lenabasum, for the treatment of pulmonary exacerbations in cystic fibrosis.
Natalie E West, Michael W Konstan, Patrick A Flume, Donald R VanDevanter, Amalia Magaret

J Cyst Fibros· July 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Daily variability of Pseudomonas aeruginosa density in cystic fibrosis sputum.
Lisa A Carmody, Lindsay J Caverly, Linda M Kalikin, Christina S Thornton, Richard H Simon, Donald R VanDevanter

J Cyst Fibros· March 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Creation of a CF-specific antibiotic spectrum index (ASI) as an antimicrobial stewardship initiative.
Jonathan D Cogen, Sonya L Heltshe, Adam W Brothers, Donald R VanDevanter, Jeffrey S Gerber

J Cyst Fibros· November 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Challenges to the optimisation of cystic fibrosis exacerbation treatment outcomes.
Christopher H Goss, Donald R VanDevanter

Eur Respir J· June 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Adjunctive Systemic Corticosteroids for Pulmonary Exacerbations of Cystic Fibrosis.
Oliver J McElvaney, Sonya L Heltshe, Katherine Odem-Davis, Natalie E West, Don B Sanders, Donald R VanDevanter

Ann Am Thorac Soc· May 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Prevalence and Clinical Impact of Respiratory Viral Infections from the STOP2 Study of Cystic Fibrosis Pulmonary Exacerbations.
Christina S Thornton, Lindsay J Caverly, Linda M Kalikin, Lisa A Carmody, Scott McClellan, Donald R VanDevanter

Ann Am Thorac Soc· April 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Re-examining baseline lung function recovery following IV-treated pulmonary exacerbations.
Sonya L Heltshe, Renee Russell, Donald R VanDevanter, Don B Sanders

J Cyst Fibros· September 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Impact of lumacaftor/ivacaftor and tezacaftor/ivacaftor on treatment response in pulmonary exacerbations of F508del/F508del cystic fibrosis.
Oliver J McElvaney, Sonya L Heltshe, Katherine Odem-Davis, Natalie E West, Don B Sanders, Donald R VanDevanter

J Cyst Fibros· September 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Corrigendum to FEV1 Variability Helps Identify Patients with Cystic Fibrosis at Risk of Greater Loss of Lung Function [The Journal of Pediatrics (2016) 116-121].
Wayne J Morgan, Donald R VanDevanter, David J Pasta, Aimee J Foreman, Jeffrey S Wagener

J Pediatr· April 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Standards of care for CFTR variant-specific therapy (including modulators) for people with cystic fibrosis.
Kevin W Southern, Carlo Castellani, Elise Lammertyn, Alan Smyth, Donald VanDevanter

J Cyst Fibros· January 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Changes in airway bacterial communities occur soon after initiation of antibiotic treatment of pulmonary exacerbations in cystic fibrosis.
Lisa A Carmody, Linda M Kalikin, Donald R VanDevanter, Gen Li, Kristopher Opron

J Cyst Fibros· September 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The Elusive Role of Airway Infection in Cystic Fibrosis Exacerbation.
Lindsay J Caverly, Donald R VanDevanter

J Pediatric Infect Dis Soc· September 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
Health care costs in a randomized trial of antimicrobial duration among cystic fibrosis patients with pulmonary exacerbations.
Laura S Gold, Ryan N Hansen, Donald L Patrick, Ashley Tabah, Sonya L Heltshe, Donald R VanDevanter

J Cyst Fibros· July 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
W
What shall we learn from TEACH?
Donald VanDevanter, John Lipuma

Thorax· June 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Retracing changes in cystic fibrosis understanding and management over the past twenty years.
Felix Ratjen, Donald R VanDevanter

J Cyst Fibros· January 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A Randomized Clinical Trial of Antimicrobial Duration for Cystic Fibrosis Pulmonary Exacerbation Treatment.
Christopher H Goss, Sonya L Heltshe, Natalie E West, Michelle Skalland, Don B Sanders, Donald R VanDevanter

Am J Respir Crit Care Med· December 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Measuring the impact of CFTR modulation on sweat chloride in cystic fibrosis: Rationale and design of the CHEC-SC study.
Edith T Zemanick, Michael W Konstan, Donald R VanDevanter, Steven M Rowe, J P Clancy

J Cyst Fibros· November 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Antimicrobial resistance: Concerns of healthcare providers and people with CF.
Wendy Bullington, Sarah Hempstead, Alan R Smyth, Pavel Drevinek, Lisa Saiman, Donald R VanDevanter

J Cyst Fibros· May 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Epidemiologic Study of Cystic Fibrosis: 25 years of observational research.
Michael W Konstan, David J Pasta, Donald R VanDevanter, Jeffrey S Wagener, Wayne J Morgan

Pediatr Pulmonol· May 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pseudomonas aeruginosa antimicrobial susceptibility test (AST) results and pulmonary exacerbation treatment responses in cystic fibrosis.
Donald R VanDevanter, Sonya L Heltshe, Jay B Hilliard, Michael W Konstan

J Cyst Fibros· March 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The march towards CFTR modulator access for all people with CF: The end of the beginning.
Donald R VanDevanter

J Cyst Fibros· March 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Evaluating assumptions of definition-based pulmonary exacerbation endpoints in cystic fibrosis clinical trials.
Donald R VanDevanter, Nicole Mayer Hamblett, Noah Simon, Joseph McIntosh, Michael W Konstan

J Cyst Fibros· January 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Association of Inhaled Antibiotics in Addition to Standard Intravenous Therapy and Outcomes of Pediatric Inpatient Pulmonary Exacerbations.
Jonathan D Cogen, Anna V Faino, Frankline Onchiri, Lucas R Hoffman, Matthew P Kronman, Donald R VanDevanter

Ann Am Thorac Soc· December 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis